IκBα mediates prostate cancer cell death induced by combinatorial targeting of the androgen receptor

Sarah L. Carter¹, Margaret M. Centenera¹,², Wayne D. Tilley¹, Luke A. Selth¹ and Lisa M. Butler¹,²*

Abstract

Background: Combining different clinical agents to target multiple pathways in prostate cancer cells, including androgen receptor (AR) signaling, is potentially an effective strategy to improve outcomes for men with metastatic disease. We have previously demonstrated that sub-effective concentrations of an AR antagonist, bicalutamide, and the histone deacetylase inhibitor, vorinostat, act synergistically when combined to cause death of AR-dependent prostate cancer cells.

Methods: In this study, expression profiling of human prostate cancer cells treated with bicalutamide or vorinostat, alone or in combination, was employed to determine the molecular mechanisms underlying this synergistic action. Cell viability assays and quantitative real time PCR were used to validate identified candidate genes.

Results: A substantial proportion of the genes modulated by the combination of bicalutamide and vorinostat were androgen regulated. Independent pathway analysis identified further pathways and genes, most notably NFKBIA (encoding IκBα, an inhibitor of NF-κB and p53 signaling), as targets of this combinatorial treatment. Depletion of IκBα by siRNA knockdown enhanced apoptosis of prostate cancer cells, while ectopic overexpression of IκBα markedly suppressed cell death induced by the combination of bicalutamide and vorinostat.

Conclusion: These findings implicate IκBα as a key mediator of the apoptotic action of this combinatorial AR targeting strategy and a promising new therapeutic target for prostate cancer.

Keywords: Prostate cancer, Androgen receptor, Combination therapy, IκBα

Background

Prostate cancer is the most commonly diagnosed cancer, and the second leading cause of cancer-related death, in men in the developed world [1]. Since Huggins, Stevens and Hodges [2] demonstrated that prostate epithelial cells require androgens for growth and survival, the mainstay of treatment for men with metastatic prostate cancer has been suppression of testosterone production by surgical or medical castration, a strategy termed androgen deprivation therapy (ADT). Whilst these treatment modalities are initially effective (reviewed in [3]), most patients eventually relapse with castrate-resistant prostate cancer (CRPC), which is incurable and the primary cause of mortality associated with this disease.

It is now well established that the mediator of androgen action, the androgen receptor (AR), plays a key role in the progression of prostate cancer following ADT, despite castrate levels of circulating testosterone. A number of mechanisms, including increased levels of the AR mRNA or protein [4–8], mutation of the AR gene to produce more active or promiscuous forms of the receptor [9–14], altered levels of AR coregulators (reviewed in [15]), the expression of constitutively active AR splice variants [16–18], and adrenal and intratumoral biosynthesis of androgens [19–23], explain continued AR signaling during ADT. As many of these mechanisms are

* Correspondence: lisa.butler@adelaide.edu.au
²Cancer Theme, South Australian Health and Medical Research Institute, Adelaide, SA 5001, Australia

© 2016 Carter et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
refractory to conventional ADT, there is considerable impetus to develop new and more potent agents targeting the androgen signaling axis. Two such agents are enzalutamide (MDV-3100), a novel AR antagonist that has demonstrated clinical activity in men who have failed both ADT and docetaxel-based chemotherapy [24], and abiraterone acetate, which targets an enzyme required for adrenal and intratumoral androgen biosynthesis. Phase III clinical trials demonstrated that these agents extend median survival of men with advanced CRPC by several months and both have received FDA approval [25].

Despite the success of enzalutamide and abiraterone, it is accepted that treatment with these agents remains essentially palliative, and that combinatorial treatment strategies targeting multiple cellular pathways in addition to androgen signaling are more likely to improve outcomes for men with CRPC. One such combination therapy comprises the AR antagonist bicalutamide and the histone deacetylase (HDAC) inhibitor vorinostat, which act synergistically together to cause death of cell line models of prostate cancer [26]. Vorinostat has a global effect on the acetylation of histones and other proteins within the cell but also reduces AR levels and activity and thereby directly targets androgen signaling [26]. The aim of this study was to interrogate the molecular mechanisms underlying the synergistic action of bicalutamide and vorinostat in prostate cancer. Through expression profiling and functional studies, we identified NFKBIA (IkBα) as a critical mediator of this therapy, and in doing so provided novel insight into AR signaling and how this might be effectively targeted in prostate cancer.

Methods

Cells and reagents

LNCaP human prostate cancer cells were purchased from the American Type Culture Collection (ATCC, Rockville, MD, USA), maintained in RPMI 1640 supplemented with 10 % fetal bovine serum (FBS) and used within a range of 20–40 passages. VCaP human prostate cancer cells were purchased from the ATCC, maintained in DMEM supplemented with sodium pyruvate, non-essential amino acids and 10 % FBS, and used within 60–70 passages. Vorinostat was obtained from Merck (New Jersey, USA) and dissolved in DMSO. Bicalutamide was obtained from Astra Zeneca (London, UK) and dissolved in ethanol. Cycloheximide was obtained from Sigma (St. Louis, MO, USA) and dissolved in DMSO. Anti-AR (N-20), anti-prostate specific antigen (PSA; C-19) and anti-heat shock protein 90 (HSP90; H-114) antibodies were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Anti-IkBα antibody was obtained from Cell Signaling Technology Inc (Danvers, MA, USA). Anti-α-tubulin antibody was obtained from Merck Millipore (Billerica, MA, USA). Horseradish peroxidase conjugated anti-rabbit, anti-mouse, and anti-sheep/goat secondary antibodies were obtained from DAKO (Botany, NSW, Australia). Non-specific, scrambled siRNA and ON-TARGETplus siRNAs targeting NFKBIA were purchased from Dharmacon (Lafayette, CO, USA) and the NFKBIA-ires-eGFP lentiviral ORF plasmid was purchased from GeneCopoeia (Rockville, MD, USA). The pLV410 eGFP lentiviral ORF plasmid was kindly provided by Dr. Philip Gregory (University of Adelaide, Adelaide, Australia).

Cell viability assays

LNCaP or VCaP cells were seeded in triplicate in 24-well plates, and allowed to attach overnight before the growth medium was replaced with medium containing vehicle control or the indicated concentrations of vorinostat, bicalutamide, or the two agents in combination. Doses were calculated based on individual dose-response curves for each agent and cell line to ensure consistency in the antiproliferative response between different cell lines ([26], Additional file 1: Figure S1). Cells were counted every 2 days using a hemocytometer and cell viability was assessed using Trypan blue dye exclusion. For sequential treatments, cells were treated with drug one for 24 h, at which point the treatment medium was removed and replaced with drug two for 48 h. To assess the effect of cycloheximide, cells were pre-treated with 10 μM cycloheximide for 1 h, which was then removed and replaced with treatment medium. Wash out experiments were performed by allowing the treatment medium to remain on the cells for 1, 2, 4, 6, 8, 16, or 24 h, at which point it was removed and replaced with drug-free medium. At each end-point cells were counted using a hemocytometer and viability assessed as above.

Microarray analysis

LNCaP cells were cultured with vehicle control, 1 μM vorinostat, 5 μM bicalutamide, or the two agents in combination for 6 h. Adjustment of the dose of bicalutamide compared to the initial cell viability assays was necessary to ensure consistency in terms of cell death between the two experiments, due to variation in the sensitivity of LNCaP cells to this agent over time. Total RNA was extracted from the cells using Trizol reagent (Life Technologies, Carlsbad, CA, USA), and RNA integrity was analyzed on an Agilent Systems Bioanalyzer. RNA from cells treated with the combination of vorinostat and bicalutamide was compared with RNA from cells treated with either vehicle control or either of the agents individually using Affymetrix Human GeneChip ST 1.0 arrays at the Adelaide Microarray Centre, as described previously [27]. Differential gene expression was
assessed by ANOVA with the p-value adjusted using a step-up multiple test correction to control the false discovery rate (FDR) [28]. Adjusted p-values < 0.05 were considered to be significant.

**Quantitative real-time PCR**

Independent RNA samples used to validate the microarray data were generated by culturing LNCaP cells with vehicle control, 1 µM vorinostat, 2.5 µM bicalutamide or the two agents in combination for 3, 6, 9 and 12 h. Total RNA (1 µg) was DNase treated with Turbo DNA Free (Ambion, Austin, TX, USA), and then reverse transcribed using an iScript cDNA Synthesis Kit (Bio-Rad, Hercules, CA, USA). qRT-PCR was performed with a 1:10 dilution of the cDNA using SYBR green (Bio-Rad) on a CFX Real-Time System (Bio-Rad). geNORM analysis was used to determine appropriate housekeeper genes for each sample set. Microarray RNA was normalized to HPRT1 and RPL19, and the independent sample set was normalized to GUSB and HPRT1. Primer sequences are listed in Additional file 2: Table S1.

**Immunoblotting**

LNCaP cells cultured with 2.5 µM bicalutamide or 1 µM vorinostat, individually and in combination, were lysed in radioimmunoprecipitation assay lysis buffer (10 mM Tris–HCl, 125 mM NaCl, 1 mM EDTA, 1% Triton X-100) supplemented with protease inhibitor cocktail (Roche, Mannheim, Germany). Lysates (20 µg) were electrophoresed through 7.5–15% SDS-polyacrylamide gels and transferred onto nitrocellulose membranes (GE Healthcare, Buckinghamshire, UK). Membranes were blocked overnight (4 °C) in 3% non-fat milk powder in TBST (tris-buffered saline containing 0.05% Tween-20) and then incubated with various primary antibodies. HSP90 (1:1000, rabbit polyclonal) and α-tubulin (1:1000, mouse monoclonal) were used to assess loading. Proteins were detected with horseradish peroxidase-conjugated secondary antibodies and visualized on autoradiography film using enhanced chemiluminescence detection (GE Healthcare).

**Transfection of siRNA and expression constructs**

For siRNA transfection, LNCaP or VCaP cells were seeded directly into transfection medium containing phenol red free (PRF) RPMI 1640, lipofectamine 2000 (Life Technologies), and reconstituted scrambled siRNA control or siRNA targeting NFKBIA at a concentration of 10 nM. Four siRNAs were tested, and #1 and #4 were found to be the most effective at achieving knockdown. After 4 h of culture, additional PRF-RPMI medium containing FBS and L-glutamine was added to the LNCaP transfection mixture, while DMEM containing FBS, L-glutamine and non-essential amino acids was added to the VCaP transfection mixture. Cells were harvested for counting and assessment of cell death using Trypan blue dye exclusion, and then lysed in RIPA buffer for immunoblot analysis three days post-treatment (LNCaP) or six days post-treatment (VCaP). The two timepoints used reflect the different growth kinetics between the two cell lines.

**Pathway analysis**

Enriched gene pathways were identified using Ingenuity Pathway Analysis (IPA), the Database for Annotation, Visualization and Integrated Discovery (DAVID), and Gene Set Enrichment Analysis. Significantly regulated genes (p < 0.05) were uploaded into IPA software v9.0 (Ingenuity Systems, CA, USA) in separate lists for the combination vs. bicalutamide alone and the combination vs. vorinostat alone. Each gene was mapped to its corresponding molecule in the Ingenuity pathways knowledge base, and core analysis identified enriched pathways and networks in the dataset against a background of the Affymetrix Human GeneChip ST 1.0 array. Lists of genes significantly regulated by the combination compared to either vehicle control or either of the individual agents were uploaded to the Functional Annotation Tool available through DAVID (https://david.ncifcrf.gov/; [29, 30]), converted to DAVID default IDs, and analyzed against a background of the microarray platform. Genes significantly regulated by the combination, either uniquely or when compared with the individual agents, were analyzed against a background of all genes significantly regulated by the combination over vehicle control. Enriched Gene Ontology (GO) biological processes and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways were identified using DAVID. Gene Set Enrichment Analysis [31] was implemented using the Broad Institute’s public GenePattern server (http://gene-pattern.broadinstitute.org/gp/pages/index.jsf), with default parameters.
efficiency was estimated at between 40 and 50%. Cells were then harvested and assessed for death using Trypan blue dye exclusion, after which they were lysed in RIPA buffer for subsequent immunoblot analysis.

**Results**

The combination of bicalutamide and vorinostat commits AR-dependent prostate cancer cells to death within 8 h of culture

Combining the AR antagonist bicalutamide with the HDAC inhibitor vorinostat induces synergistic cell death of prostate cancer cells, with multiple features characteristic of apoptosis [26]. In order to accurately tailor the design of microarray studies, the timing and cellular requirements for cell death induced by the combination were determined in AR-dependent prostate cancer cells. A basal level of cell death of approximately 10% in LNCaP cells and 15–30% in VCaP cells was observed when cells were treated with vehicle control and low doses of bicalutamide (2.5 μM) or vorinostat (1 μM) alone (Fig. 1a). A significant increase in cell death was observed in LNCaP (up to 30%) and VCaP (up to 50%) cells treated with the combination of bicalutamide and vorinostat (Fig. 1a). To determine whether the synergy was due to one agent sensitizing the cells to the other agent, LNCaP cells were treated sequentially with each individual agent alone and subsequently assessed for viability. Maximal cell death was only achieved when both agents were simultaneously present in culture, not when agents were used sequentially (Fig. 1b). Pre-treatment with the protein synthesis inhibitor cycloheximide indicated that cell death induced by the combination is at least partially reliant on de novo protein synthesis. High dose vorinostat, known to rely on de novo protein synthesis for induction of cell death [32], was included as a positive control (Fig. 1c). Finally, drug wash out studies

![Fig. 1](https://example.com/fig1.png)

**Fig. 1** Characterization of cell death caused by the combination of bicalutamide and vorinostat. LNCaP cells (2 x 10⁶ cells per well in 24-well plates) were cultured in triplicate wells with either vehicle control [VEH] bicalutamide [BIC] (2.5 μM) or vorinostat [VOR] (1 μM), individually and in combination [BIC + VOR], in RPMI 1640 supplemented with 10% FBS. VCaP cells (5 x 10⁶ cells per well in 24-well plates) were cultured in triplicate wells with bicalutamide (1.25 μM) or vorinostat (0.5 μM), individually and in combination, in DMEM supplemented with sodium pyruvate, non-essential amino acids and 10% FBS. a LNCaP cells were counted at 2, 4 and 6 days of culture with bicalutamide and vorinostat, while VCaPs were counted at 4, 6 and 8 days of culture. b LNCaP cells were cultured with treatment one (1) for 24 h, which was removed and replaced with treatment two (2) for 48 h. (C) LNCaP cells were pre-treated for 1 h with cycloheximide (10 μM), and then cultured for 3 d with indicated treatments (HIGH BIC = 50 μM, HIGH VOR = 7.5 μM). d LNCaP cells were cultured with indicated treatments, and at 1, 2, 4, 6, 8, 16, or 24 h treatment medium was removed and replaced with normal culture medium not containing either agent until a total of 72 h of culture. At each end point, cells were counted using a haemocytometer, and assessed for viability using trypan blue dye exclusion. Cell death is expressed as a percentage of total cell number. Values indicated are the mean of triplicate wells ± SEM, and are representative of three independent experiments. * = p < 0.05 using one-way ANOVA with Bonferroni post-hoc test
determined the timing of molecular events leading to prostate cancer cell death. A percentage of death comparable to a full 3 days of combination therapy (~30 %) was observed when the cells had been cultured with the drugs for at least 8 h or more before drug washout and subsequent culture with standard culture media for 3 days (Fig. 1d), indicating that molecular events that induce irreversible cell death occur within 6–8 h of treatment.

**Gene expression profiles in LNCaP cells treated with bicalutamide and vorinostat**

Gene expression profiling of LNCaP cells treated with vehicle control, bicalutamide or vorinostat alone and a combination of the agents was carried out to identify the molecular mechanisms underlying combination-induced cell death. A treatment time of 6 h was selected based on the wash out study (Fig. 1d). A total of 7497 genes were significantly modulated \((p < 0.05)\) by the agents alone or in combination when compared with vehicle control (Fig. 2a). Of the 5873 genes modulated by the combination, ~70 % were also modulated by vorinostat alone, ~2 % were also modulated by bicalutamide alone, and ~7 % were modulated by both of the individual agents. A total of 1209 genes (~20 %) were uniquely regulated by the combination. As expected of an HDAC inhibitor, which increases histone acetylation and thereby promotes chromatin accessibility and transcriptional activation, vorinostat induced significantly more genes than it repressed (Fig. 2b). In contrast, bicalutamide alone or the combination induced and repressed approximately equal proportions of genes. Three genes – PMEPA1, PGM2L1 and STEAP1 - were selected as representative examples of the range of different expression patterns most commonly observed, and quantified by qRT-PCR in the microarray samples and an independently generated sample set. All three genes showed a comparable pattern of regulation in both the microarray and the validation RNA sets (Additional file 3: Figure S2), indicating that the microarray data was robust.

**Combined bicalutamide and vorinostat treatment antagonizes the expression of androgen-regulated genes**

As both bicalutamide and vorinostat have been shown to modulate AR levels and activity, it was feasible that cell death induced by the combination results from enhanced blockade of androgen signaling and the consequent antagonism of androgen-regulated genes required for growth and survival. To assess this possibility, genes modulated by the combination therapy were compared with LNCaP androgen-regulated genes defined in a previous study by Wang and colleagues [33]. Approximately half of the androgen-regulated genes in LNCaP cells were significantly altered by the combination treatment (Fig. 3a). As expected, gene set enrichment analysis (GSEA) revealed that the genes upregulated by androgen treatment were generally repressed by the combination treatment (Fig. 3b).

A high proportion of the genes significantly regulated by the combination were also regulated to a similar magnitude by bicalutamide or vorinostat treatment alone. However, as induction of cell death was restricted to the combination treatment, we focused on the genes that showed selective alteration with the combination compared to the individual agents. Combination treatment altered 412 genes compared to vorinostat alone and 6035 genes compared to bicalutamide alone. We refined these lists to include only the genes that were significantly altered \((p < 0.05;\) ANOVA with FDR adjustment) by the combination when compared to both of the individual agents, which yielded 216 genes (Fig. 3c; full list shown in Additional file 4: Table S2). Interestingly, approximately half of the genes in this set have been reported to be androgen-regulated (Fig. 3d), suggesting that enhanced blockade of androgen signaling by the combination was likely to be a mechanism of cell death. To test this hypothesis, six known androgen regulated genes, **KLK2, KLK3** (PSA), **NFX3-1, IGF1R, NFKBIA** and **C1orf116**, that
exhibited significantly greater regulation by the combination in the microarray compared with individual agents alone were analyzed by qRT-PCR in an independent sample set. Each of these genes is frequently used to assess androgen receptor signaling (32). All six genes were significantly down regulated (>2-fold) after 6 h of treatment with the combination when compared with vehicle control (Fig. 4a). For KLK2, KLK3 (PSA), NKX3-1, IGF1R, and C1orf116, the effect of the combination therapy largely paralleled that of bicalutamide treatment alone; comparable activity of both treatments was also observed at the protein level for PSA (KLK3) (Fig. 4b). Interestingly, NFKBIA, an androgen regulated gene that encodes an inhibitor of the NF-κB complex (IκBα), was significantly and consistently down regulated by the combination compared to individual treatments of both bicalutamide and vorinostat at 6 h of culture. Collectively, these observations suggested that prostate cancer cell death induced by the combination may not be occurring solely due to more complete blockade of androgen signaling, and other pathways involving a subset of androgen-regulated and non-androgen-regulated genes are likely to be involved.

Loss of NFKBIA contributes to cell death induced by the combination of bicalutamide and vorinostat
To investigate other cellular pathways that potentially mediate the effects of the combination therapy, three
Fig. 4 (See legend on next page.)
independent gene annotation enrichment programs were utilized: Ingenuity Pathway Analysis (IPA), the Database for Annotation, Visualization and Integrated Discovery (DAVID), and GSEA. Due to the significant overlap between pathways enriched by the combination and the individual agents (Additional file 5: Table S3), we restricted our analysis to the set of 216 genes (Fig. 3c) that were significantly regulated by the combination treatment when compared to the effects of the individual agent treatments. This refined gene set was enriched for a number of pathways potentially important in the synergistic action of the combination therapy, including pathways involved in cell cycle, cell death and cell motility, such as p53 signaling, Jak-STAT signaling, and axon guidance (Table 1).

Interestingly, the androgen-regulated gene NFKBIA (nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha) was present in many of these pathways.

### Table 1

| Pathway ID | Genes involved | p-value | Pathway ID | Genes involved | p-value |
|------------|----------------|---------|------------|----------------|---------|
| Molecular Mechanisms of Cancer | FYN, PMAIP1, NFKBIA, GNA15, RHOU, PLCB1 | 8.91 x 10^-7 | Pathways in cancer | IGF1R, LAMA1, LAMA3, KLK3, NKX3-1, NFKBIA, ZBTB16, PIAS1, MMP1 | 1.01 x 10^-4 |
| Inositol Phosphate Metabolism | SYNJ1, SGK1, PLCB1, MAK | 2.75 x 10^-6 | Focal adhesion | IGF1R, LAMA1, LAMA3, FYN, THBS1, VCL | 2.66 x 10^-6 |
| p53 Signaling | PMAIP1, TP53INP1, THBS1, SNAI2, TNFRSF10B | 3.16 x 10^-6 | Jak-STAT signaling pathway | SOCS2, LIFR, PIAS1, IL6R | 2.48 x 10^-4 |
| Prostate Cancer Signaling | NFKBIA, NKX3-1, KLK3 | 8.13 x 10^-5 | Small cell lung cancer | LAMA1, LAMA3, NFKBIA, PIAS1 | 2.84 x 10^-4 |
| Aldosterone Signaling in Epithelial Cells | SGK1, PLCB1, DNAJB14 | 2.88 x 10^-4 | Prostate cancer | IGF1R, KLK3, NKX3-1, NFKBIA | 3.02 x 10^-4 |
| Glioma Signaling | IGF1R | 3.63 x 10^-4 | Adherens junction | IGF1R, FYN, SNA2, VCL | 3.22 x 10^-4 |
| Biosynthesis of Steroids | HMGCR | 5.25 x 10^-4 | Axon guidance | NRP1, FYN, NTNG1, EFNA5 | 4.08 x 10^-4 |
| NRF2-mediated Oxidative Stress Response | GSTM2, MAF, DNAJB14, ABC4 | 0.0010 | ECM-receptor interaction | LAMA1, LAMA3, THBS1 | 0.0018 |
| Xenobiotic Metabolism Signaling | GSTM2, MAF, CYP3A5 | 0.0013 | Long-term depression | IGF1R, GUCY1A3, PLCB1 | 0.0029 |
| TWEAK Signaling | NFKBIA | 0.0016 | Adipocytokine signaling pathway | NFKBIA, ACSL3, CAMKK2 | 0.0038 |
| TNFR1 Signaling | NFKBIA | 0.0018 | Gap junction | TUBB, GUCY1A3, PLCB1 | 0.0047 |
| TNFR2 Signaling | NFKBIA | 0.0023 | p53 signaling pathway | TNFRSF10B, PMAIP1, THBS1 | 0.0064 |
| Role of CHK Proteins in Cell Cycle Checkpoint Control | HUS1 | 0.0026 | T cell receptor signaling pathway | CD8B, FYN, NFKBIA | 0.0073 |
| B Cell Receptor Signaling | NFKBIA | 0.0037 | Purine metabolism | POLE2, GUCY1A3, PDE9A | 0.0095 |
| Prolactin Signaling | FYN, SOCS2 | 0.0038 | Cytokine-cytokine receptor interaction | TNFRSF10B, LIFR, IL6R | 0.0103 |
| PI3K/AKT Signaling | NFKBIA | 0.0060 | Hematopoietic cell lineage | CD8B, IL6R | 0.0355 |
| Insulin Receptor Signaling | FYN, SGK1 | 0.0065 | ABC transporters | ABC4, ABCG1 | 0.0462 |
| Death Receptor Signaling | NFKBIA, TNFRSF10B | 0.0083 | Drug metabolism | CYP3A5, NAT1 | 0.0462 |
implying that it may be a key regulator of the combination therapy. Supporting this concept, the network tool in IPA identified \( \text{NFKBIA} \) or its associated genes as central molecules in the top two significantly enriched networks - Cell Morphology, Cellular Movement and Cell Signaling, and Cellular Movement, Drug Metabolism, Endocrine System Development and Function (Additional file 6: Figure S3, Additional file 7: Table S4). Furthermore, when scrutinizing the list of 216 genes with enhanced regulation by the combination, \( \text{NFKBIA} \) was one of the most markedly down-regulated genes in response to combination treatment (>1.5 fold change) when compared to both of the individual agents alone (Additional file 4: Table S2). These results collectively implicated a role for \( \text{NFKBIA} \) in the molecular action of the combination treatment.

Down-regulation of \( \text{NFKBIA} \) by the combination treatment was validated in a set of RNA samples generated from an independent time-course experiment (Fig. 5a). \( \text{NFKBIA} \) mRNA was repressed within 3 h by the combination compared to both vehicle (approximately 4-fold down-regulated) and to each agent individually (approximately 2-fold). This repression was maintained for at least 6 h of culture, but returned to levels similar to bicalutamide alone by 12 h. Western blot analysis showed that protein levels of the corresponding protein, I\( \kappa \)B\( \alpha \), were also reduced by the combination (Fig. 5b).

**Fig. 5** The effect of combinatorial AR targeting on \( \text{NFKBIA} \) levels and p53 signaling. **a** The expression of \( \text{NFKBIA} \) over a timecourse was normalized to \( \text{GUSB} \) and \( \text{HPRT1} \). Relative expression is the fold change expressed relative to vehicle control. Values indicated are the mean of technical and biological replicates ± SEM, and are representative of three independent experiments. * = \( p < 0.05 \) using one-way ANOVA with Bonferroni post-hoc test, compared with bicalutamide or vorinostat individually. **b** Western blot analysis of lysates from LNCaP cells cultured with either vehicle control (VEH), 1 \( \mu \text{M} \) vorinostat (VOR), 2.5 \( \mu \text{M} \) bicalutamide (BIC) or the combination of 1 \( \mu \text{M} \) vorinostat and 2.5 \( \mu \text{M} \) bicalutamide (BIC+VOR) for 12, 48, or 96 h. Steady state levels of I\( \kappa \)B\( \alpha \) are shown, and tubulin is shown as a loading control. **c** mRNA expression levels of \( \text{TP53INP1} \) and \( \text{CDK1NA} \) (p21) are shown as for \( \text{NFKBIA} \). * = \( p < 0.05 \) using one-way ANOVA with Bonferroni post-hoc test.
The significant and rapid modulation of NFKBIA suggested that it might be an upstream initiator of processes involved in cell death mediated by the combination therapy. NFKBIA is a known regulator of the NF-κB and p53 signaling pathways [34], and p53 signaling was identified as a highly enriched pathway in cells treated with the combination (Table 1). Given this association between NFKBIA (IkBα) and p53 signaling, the expression of two p53 inducible genes, TP53INP1 and CDKN1A (p21) was measured. At early time points of 3 and 6 h, neither TP53INP1 nor CDKN1A mRNA was altered by combination therapy or either of the agents individually. However, at 12 h of culture, the combination induced expression of both genes by approximately four-fold when compared with vehicle control, and two-fold when compared with bicalutamide or vorinostat (Fig. 5c). The up-regulation of TP53INP1 and CDKN1A occurred after the decrease in NFKBIA, and at a similar time point to the observed loss of IκBα protein (Fig. 5b), supporting the hypothesis that the combination mediates NFKBIA-dependent activation of p53 signaling.

Specific knockdown or overexpression of NFKBIA alters LNCaP cell viability and response to the combination of bicalutamide and vorinostat

To investigate the functional significance of NFKBIA for prostate cancer cell viability and the observed drug responses, siRNA-mediated knockdown of NFKBIA was performed in both LNCaP and VCaP cells. Transfection with two different siRNAs targeting NFKBIA resulted in a marked reduction in IκBα protein levels at 3 days post-treatment for LNCaPs, and 6 days post-treatment for VCaPs (Fig. 6a). Depletion of IκBα with siRNA #1 or #4 caused a significant induction of cell death in LNCaP cells (23–25 % compared to the basal level of 10 % observed with non-specific siRNA; \( p < 0.05 \); Fig. 6b) and VCaP cells (25 % compared to the basal level of 15 % observed with non-specific siRNA; \( p < 0.05 \); Fig. 6b). This data indicated that IκBα is an important regulator of...
prostate cancer cell viability in two separate AR-positive cell lines. Moreover, IκBα depletion caused cell death of a similar magnitude to that observed with combination treatment, and significantly enhanced cell death caused by the combination (Additional file 8: Figure S4).

To directly assess the importance of IκBα downregulation in combination therapy-mediated cell death, we tested whether ectopic over-expression of NFKBIA altered response to the combination treatment. Transfection efficiency of the NFKBIA expression construct, which co-expresses GFP, was estimated at between 30 and 50 % by flow cytometry and fluorescent microscopy (data not shown). Increased levels of IκBα protein after transfection, compared to cells transfected with a control GFP-only expression vector, were confirmed by immunoblotting (Fig. 6c). Treatment of cells overexpressing GFP with the combination of vorinostat and bicalutamide induced approximately 34 % cell death which, as expected, was significantly greater than in vehicle-treated controls. By contrast, in cells overexpressing IκBα, cell death caused by the combination was significantly reduced to ~17 %, which was not significantly different to the basal cell death observed with vehicle control treatment. This finding indicates that downregulation of IκBα is an essential requirement for synergistic cell death induced by the combination of bicalutamide and vorinostat.

Discussion

Metastatic prostate cancer inevitably becomes resistant to current hormonal therapies and, consequently, combinatorial therapeutic approaches that may be more efficacious and less prone to resistance-associated failure have garnered significant interest. We have previously shown that combining the AR antagonist bicalutamide with the HDAC inhibitor vorinostat synergistically induces growth arrest and cell death in prostate cancer cells. Importantly, this combination approach uses doses of both agents that are individually sub-effective [26], implying that it would minimize dose-related toxicity. The current study provides new insight into the molecular mechanism by which these disparate agents interact synergistically to induce death of prostate cancer cells, and implicates IκBα, a regulator of the NF-κB and p53 pathways, as a critical factor for prostate cancer cell viability and treatment response.

Given that vorinostat and bicalutamide both target AR, we initially hypothesized that the combination of these two agents would enhance blockade of androgen signaling, a pathway that promotes growth and survival of prostate cancer cells. This hypothesis was reinforced by previous work from our laboratory demonstrating that the combination treatment induced death only in cells with a functional AR signaling axis, and that addition of excess dihydrotestosterone (DHT) to the system prevented cell death [26]. The genome-wide microarray expression data generated in the current study also supported this hypothesis. Specifically, many androgen-regulated genes were significantly altered by the combination compared to individual agents, and pathway analysis demonstrated deregulation of androgen signaling and prostate cancer networks by the combination treatment. Interestingly, for six known androgen regulated genes, we did not observe consistently greater downregulation by the combination therapy in an independent set of RNA samples. This could suggest that enhanced androgen blockade is not the substantive mechanism by which the combination exerts its effect. However, this subset of genes only represents approximately 10 % of the genes significantly regulated by both DHT and the combination (when compared with the individual agents), and 1 % of the total genes significantly regulated by both DHT and the combination (when compared with vehicle control). It is possible that small changes to a large number of androgen regulated genes is an important factor in the mechanism of action of the combination therapy, or that these cumulative changes are able to sensitize the prostate cancer cells to HDAC inhibition.

While the importance of enhanced blockade of androgen signaling by the combination treatment remains ambiguous, the expression data revealed that this treatment also modulates a multitude of other critical cellular processes. For example, p53 signaling and other pathways involved in cell cycle arrest and cell death were highly enriched in genes modulated by the combination. In considering potential mediators of the synergistic interaction between vorinostat and bicalutamide, we noted that our pathway analyses consistently implicated an inhibitor of NF-κB, NFKBIA, in this phenomenon. Interestingly, NFKBIA is an androgen regulated gene, and the protein encoded by this gene, IκBα, is best known as an inhibitor of NF-κB signaling. However, IκBα can also inhibit p53 signaling and thereby functions dichotomously to either block p53-mediated cell death or NF-κB-mediated cell growth [34–37], with the final phenotypic outcome likely depending on the relative levels of NF-κB and p53 within a given cell. At a mechanistic level, IκBα sequesters NF-κB or p53 in the cytoplasm in an inactive complex; following various stimulatory events, IκBα is phosphorylated and targeted for degradation via the ubiquitin-proteasome pathway, relieving inhibition of these factors. With respect to prostate cancer cell death, we observed rapid downregulation of NFKBIA in cells treated with the combination of bicalutamide and vorinostat that was associated with increased expression of TP53INP1 and CDKN1A, two commonly known p53-inducible genes, and induction of cell death. Taken
together, this data suggests that, in the context of the combination therapy, loss of IkBα results in cell death, which may be facilitated by the induction of p53 signaling. This hypothesis is supported by the observation that knockdown of NFKBIA in the absence of drug treatment resulted in a similar level of cell death to that observed with the combination in two independent prostate cancer cell lines. Moreover, co-treatment with NFKBIA siRNA and the combination therapy caused significantly more cell death than either individual treatment. Importantly, overexpression of NFKBIA almost completely negated the effect of the combination treatment on cell death.

Two other observations arising from the current study are worth noting for their clinical ramifications. First, the combination of bicalutamide and vorinostat was efficacious in models with a mutant (LNCaP) or amplified wild-type (VCaP) AR gene. Given that many clinical prostate cancers are characterized by aberrant AR signaling, and that intra-tumoral heterogeneity may result in foci that each potentially have structurally different androgen receptors, this is a promising feature of the combination therapy. Second, both vorinostat and bicalutamide are required simultaneously in culture for induction of cell death, indicating that if sensitization is happening it occurs rapidly. This finding indicates that future clinical testing will require the agents to be dosed together and not sequentially.

**Conclusion**

In summary, we have defined a novel mechanism of action by which bicalutamide and vorinostat, when used in combination, mediate death of prostate cancer cells. While enhanced blockade of androgen signaling is potentially important, we have demonstrated that other cellular pathways also play critical roles. Specifically, IkBα was identified as a critical regulator of therapy-mediated cell death; this factor may have potential either as a new therapeutic target and/or a marker of drug response. The ability to monitor molecular markers of apoptotic response to such therapeutic strategies will aid in the clinical development of this combinatorial approach for treatment of prostate cancer.

**Additional files**

- Additional file 1: Figure S1. Dose response curves of bicalutamide and vorinostat in VCaP cells. VCaP cells (5 × 10⁵ per well in 24-well plates) were cultured in triplicate wells with bicalutamide or vorinostat at the indicated doses in DMEM medium supplemented with sodium pyruvate, non-essential amino acids and 10 % FBS. Cells were counted using a haemocytometer, and assessed for viability using trypan blue dye exclusion. Cell death is expressed as a percentage of total cell number. (PPTX 213 kb)
- Additional file 2: Table S1. Primer Sequences. (DOCX 13 kb)
- Additional file 3: Figure S2. Microarray validation by RT-PCR. Validation of the microarray results, using three of the most markedly changed genes: PMERAI was down-regulated by all three treatments, PAG021 was up-regulated by vorinostat and the combination but not bicalutamide, and STEAP1 was down-regulated uniquely by the combination. Expression values taken from the microarray, qRT-PCR on three of the biological replicates used in the microarray, and qRT-PCR on an independently generated sample set were compared for these three genes. Three technical replicates for each biological replicate were analysed, and the expression normalised to RPL32 and GUSB. Fold change was determined over vehicle control. Values indicated are the mean of technical and biological replicates ± SEM; p < 0.05 using one-way ANOVA with Tukey post-hoc test, compared with vehicle control (*), vorinostat (#), or bicalutamide (>). (TIF 6450 kb)
- Additional file 4: Table S2. List of 216 genes significantly regulated by combination therapy versus each individual agent. (DOCX 28 kb)
- Additional file 5: Table S3. Comparison of pathway analyses for bicalutamide, vorinostat, or the combination versus vehicle control. KEGG pathways. (DOCX 24 kb)
- Additional file 6: Figure S3. Enriched networks in list of 216 genes with enhanced regulation by the combination. The network tool in Ingenuity Pathway Analysis identified the networks of Cell Morphology, Cellular Movement and Cell Signaling (A), as well as Cellular Movement, Drug Metabolism, Endocrine System Development and Function (B), as the two most significantly enriched by the combination treatment when compared to the individual agents (list of 216 genes). Colors indicate the regulation by the combination when compared to both of the individual agents – green is downregulation, red is upregulation and half green half red means that the combination upregulated the gene compared to one treatment, and downregulated compared to the other. The lines in between the genes represent a network connection. (PPTX 18374 kb)
- Additional file 7: Table S4. IPA network analysis for genes regulated by the combination when compared to individual doses of bicalutamide and vorinostat. (DOCX 18 kb)
- Additional file 8: Figure S4. Knockdown of NFKBIA enhances the cell death effect observed with the combination therapy. (A) Western blot analysis of lysates from LNCaP cells transfected with either non-specific (N.S.) or specific siRNA (1) and siRNA (4) NFKBIA siRNA and then treated with vehicle control (VC), 2.5 μM bicalutamide (BIC), 1 μM vorinostat (VOR), or the combination of 2.5 μM bicalutamide and 1 μM vorinostat (BIC + VOR). Steady state levels of IkBα at day three of treatment are shown, with hsp90 as a loading control. (B) Cells were counted at three days of treatment, and assessed for viability using trypan blue dye exclusion. Cell death is expressed as a percentage of total cell number. Values indicated are the mean of triplicate wells ± SEM, and are representative of three independent experiments. * = p < 0.05 using t-test. (PPTX 213 kb)

**Abbreviations**

ADT: androgen deprivation therapy; AR: androgen receptor; CRPC: castration-resistant prostate cancer; DAVID: database for annotation, visualization and integrated discovery; DHT: 5α-dihydrotestosterone; FBS: fetal bovine serum; FDR: false discovery rate; GFP: green fluorescent protein; GO: gene ontology; GSEA: gene set enrichment analysis; HDAC: histone deacetylase; HSP90: heat shock protein 90; IPA: Ingenuity pathway analysis; KEGG: Kyoto encyclopedia of genes and genomes; NFkBIA: nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha; PRF: phenol red-free; PSA: prostate-specific antigen.

**Competing interests**

The authors declare that they have no competing interests.

**Authors’ contributions**

SLC carried out the molecular studies, participated in the microarray profiling and analysis, participated in the design of the study and drafted the manuscript. MWC participated in the microarray profiling studies and the manuscript drafting. WDT participated in the design of the study and manuscript drafting. LAS participated in microarray analysis, design of the study, and manuscript drafting. LMB conceived of the study, designed the study and participated in manuscript drafting. All authors read and approved the final manuscript.
Acknowledgements

This work was supported by the National Health and Medical Research Council of Australia (627185 to WDT & LMB), Cancer Australia (627229 and 1012337 to LMB & WDT), the Royal Adelaide Hospital Research Committee (to MMC, LMB & WDT), an infrastructure grant from the Prostate Cancer Foundation of Australia (2011/0452 to WDT), Cancer Council of South Australia Senior Research Fellowship (to LMB), a Future Fellowship from the Australian Research Council (FT13010014 to LMB), Young Investigator grants from the Prostate Cancer Foundation of Australia (LAS, YI 0810; MMC, YI 0412), a Young Investigator Award from the Prostate Cancer Foundation (the Foundation 14 award; LAS) and the Lions Medical Research Foundation Post-Graduate Scholarship (SLC). We thank Ms Natalie Ryan for her assistance in generating material for the microarray study, Ms Joanna Gillis for her assistance in generating material for the VCaP knockdown studies, Ms Heather Armstrong for technical assistance, and Dr Paul Neilson for expert advice on ps5 signaling.

Received: 6 July 2015 Accepted: 16 February 2016

Published online: 23 February 2016

References

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60(5):277–300.
2. Huggins C, Stevens Jr RE, Hodges CV. The effect of castration on advanced carcinoma of the prostate gland. Arch Surg. 1941;43:209.
3. Klitz L. Maximal androgen blockade for advanced prostate cancer. Best Pract Res Clin Endocrinol Metab. 2008;22(2):331–40.
4. Visakorpi T, Hyytinen E, Koivisto P, Tanner M, Keinanen R, Palmberg C, et al. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet. 1995;9(4):401–6.
5. Koivisto P, Kononen J, Palmberg C, Tammela T, Hyytinen E, Isola J, et al. Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res. 1997;57(2):314–9.
6. Linj M, Savinainen KJ, Saramaki OR, Tammela TL, Vessella RL, Visakorpi T. Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res. 2001;61(9):3550–5.
7. Edwards J, Krishna NS, Grigor KM, Bartlett JM. Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer. Br J Cancer. 2003;89(3):552–6.
8. Chen CD, Welibe DS, Tran C, Baek SH, Chen R, Vessella R, et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med. 2004;10(1):133–9.
9. Taplin ME, Bubley GJ, Shuster TD, Frantz ME, Spooner AE, Ogata GK, et al. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med. 1995;332(21):1393–8.
10. Tilly WD, Buchanan G, Hickey TE, Bentel JM. Mutations in the androgen receptor gene are associated with progression of human prostate cancer to androgen independence. Clin Cancer Res. 1996;2(2):277–85.
11. Fenton MA, Shuster TD, Fertig AM, Taplin ME, Kolvenbag G, Bubley GJ, et al. Functional characterization of mutant androgen receptors from androgen-independent prostate cancer. Clin Cancer Res. 1997;3(8):1383–8.
12. Marcelli M, Istran M, Marian S, Sutherland R, Nigam R, Murthy L, et al. Androgen receptor mutations in prostate cancer. Cancer Res. 2000;60(4):944–9.
13. Buchanan G, Yang M, Harris JM, Nahim HS, Han G, Moore N, et al. Mutations at the boundary of the hinge and ligand binding domain of the androgen receptor confer increased transactivation function. Mol Endocrinol. 2001;15(1):46–56.
14. Han G, Buchanan G, Istran M, Harris JM, Yu X, Demayo FJ, et al. Mutation of the androgen receptor causes oncogenic transformation of the prostate. Proc Natl Acad Sci U S A. 2005;102(4):1151–6.
15. Chmeln R, Buchanan G, Neuf EF, Tilly W, Greenberg NM. Androgen receptor coregulators and their involvement in the development and progression of prostate cancer. Int J Cancer. 2007;120(4):719–33.
16. Dehn SM, Schmidt LJ, Heemkes HV, Vessella RL, Tindall DJ. Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res. 2008;68(13):5469–77.
17. Guo Z, Yang X, Sun F, Jiang R, Linn DE, Chen H, et al. A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Res. 2009;69(6):2305–13.
18. Watson PA, Chen YF, Balbas MD, Wongvipat J, Socci ND, Viale A, et al. Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor. Proc Natl Acad Sci U S A. 2010;107(39):16759–65.
19. Stanbrough M, Bubley GJ, Ross K, Golub TR, Rubin MA, Penning TM, et al. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res. 2006;66(5):2815–25.
20. Montgomery RB, Mostaghel EA, Vessella R, Hess DL, Kalhorn TF, Higano CS, et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res. 2008;68(1):4447–54.
21. Mohler JL, Gregory CW, Ford 3rd OH, Kim D, Weaver CM, Petrus P, et al. The androgen axis in recurrent prostate cancer. Clin Cancer Res. 2004;10(2):440–8.
22. Nishiyama T, Hashimoto Y, Takahashi K. The influence of androgen deprivation therapy on dihydrotestosterone levels in the prostatic tissue of patients with prostate cancer. Clin Cancer Res. 2004;10(21):7121–6.
23. Mostaghel EA, Page ST, Lin DW, Fazli L, Coleman IM, True LD, et al. Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer. Cancer Res. 2007;67(10):5033–41.
24. Scher HI, Beer TM, Higano CS, Anand A, Taplin ME, Efstathiou E, et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1/2–1 study. Lancet. 2010;375(9724):1437–46.
25. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364(21):1995–2005.
26. Marrocco DK, Tilly WD, Bianco-Miotto T, Evdokou A, Scher HI, Riffkind RA, et al. Suberylanilide hydrazinic acid (votinostat) represses androgen receptor expression and acts synergistically with an androgen receptor antagonist to inhibit prostate cancer cell proliferation. Mol Cancer Ther. 2007;6(11):151–68.
27. Moore NL, Buchanan G, Harris JM, Seth LA, Bianco-Miotto T, Hanson AR, et al. An androgen receptor mutation in the MDA-MB-453 cell line model of molecular aaprice breast cancer compromises receptor activity. Endocr Relat Cancer. 2012;19(19):599–613.
28. Benjmini YBH. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Roy Stat Soc Ser B (Methodological). 1995;57:289–300.
29. Dennis JR, Bohn BT, Hosack DA, Yang J, Gao W, Lane HC, et al. DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol. 2003;4(5):3.
30. da Huang W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009;4(1):44–57.
31. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102(43):15545–50.
32. Bolden JE, Shi W, Jankowski K, Kan CY, Cluze L, Martin BP, et al. HDAC inhibitors induce tumor-cell-selective pro-apoptotic transcriptional responses. Cell Death Dis. 2013;4:e619.
33. Wang Q, Li W, Zhang Y, Yuan X, Xu K, Yu J, et al. Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer cell. Cell. 2009;138(2):245–56.
34. Chang NS. The non-ankyrin C terminus of I kappa B alpha physically interacts with p53 in vivo and dissociates in response to apoptotic stress, hypoxia, DNA damage, and transforming growth factor-beta 1-mediated growth suppression. J Biol Chem. 2002;277(12):10323–31.
35. Ryan KM, Ernst MK, Rice NR, Vouiden KH. Role of NF-kappaB in p53-mediated programmed cell death. Nature. 2000;404(6780):892–7.
36. Fujioka S, Schmidt C, Scolas GM, Li Z, Pelciano H, Peng B, et al. Stabilization of p53 is a novel mechanism for proapoptotic function of NF-kappaB. J Biol Chem. 2004;279(26):27549–59.
37. Puzynski K, Bertolusso R, Lipniacki T. Crosstalk between p53 and nuclear factor-B systems: pro- and anti-apoptotic functions of NF-B. IET Syst Biol. 2009;3(5):356–67.